Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML0335

Sigma-Aldrich

Remacemide hydrochloride

≥98% (HPLC)

Synonym(s):

2-Amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, FPL 12924AA, PR 934-423A

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C17H20N2O · HCl
CAS Number:
Molecular Weight:
304.81
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: >10 mg/mL

storage temp.

room temp

SMILES string

Cl.CC(Cc1ccccc1)(NC(=O)CN)c2ccccc2

InChI

1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H

InChI key

HYQMIUSWZXGTCC-UHFFFAOYSA-N

Biochem/physiol Actions

Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties. Remacemide also been shown to block voltage-dependent sodium channels.
Remacemide possesses neuroprotective and anti-epileptic actions. It supports reducing the frequency of seizures. Remacemide is also known to be a potential therapeutic for Huntington′s disease.

Features and Benefits

This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Eye Dam. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

D Chadwick et al.
Seizure, 9(8), 544-550 (2001-02-13)
Forty patients (33 male, 7 female) with refractory epilepsy were randomized to receive ascending weekly doses of adjunctive remacemide hydrochloride in a b.i.d. or q.i.d. regimen, or placebo for up to 1 month. Assessments included routine physical examination and laboratory
Robert Małek et al.
Polish journal of pharmacology, 55(5), 691-698 (2004-01-06)
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is to keep the patient free of seizures without interfering with normal brain function. Unfortunately, about 30% of all epilepsies
Gabriele Schilling et al.
Experimental neurology, 187(1), 137-149 (2004-04-15)
The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological
K A Wesnes et al.
Epilepsy & behavior : E&B, 14(3), 522-528 (2008-12-30)
An international trial comparing remacemide hydrochloride with carbamazepine was undertaken in individuals with newly diagnosed epilepsy using a novel double-blind, parallel-group, double triangular sequential design. Patients with two or more partial or generalized tonic-clonic seizures in the previous year were
O Devinsky et al.
Seizure, 11(6), 371-376 (2002-08-06)
This multicentre, randomised, double-blind, placebo-controlled, parallel-group study investigated the efficacy, safety and pharmacokinetics of remacemide hydrochloride in adult patients ( n= 59) with refractory epilepsy, undergoing reduced or discontinued antiepileptic drug (AED) usage, as part of an evaluation for epilepsy

Articles

We offers many products related to ion channel family glutamate receptors for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service